CSO

Firestorm Labs and Congresswoman Sara Jacobs (CA-51) Celebrate Opening of State-of-the-Art Headquarters in San Diego

Retrieved on: 
Wednesday, April 3, 2024
Firestorm, Government, Growth, Golden Joystick Awards, Unitary state, Entrepreneurship, Military, SAN, Distinguishing, Unmanned aerial vehicle, UAS, House, CSO, Representative, Tempest

SAN DIEGO, April 3, 2024 /PRNewswire/ -- Yesterday, Firestorm Labs, a defense technology startup spearheading expeditionary manufacturing of Unmanned Aerial Systems (UAS), proudly celebrated the grand opening of its state-of-the-art, 14,000 square foot headquarters in Kearny Mesa, San Diego, California.

Key Points: 
  • SAN DIEGO, April 3, 2024 /PRNewswire/ -- Yesterday, Firestorm Labs, a defense technology startup spearheading expeditionary manufacturing of Unmanned Aerial Systems (UAS), proudly celebrated the grand opening of its state-of-the-art, 14,000 square foot headquarters in Kearny Mesa, San Diego, California.
  • During her keynote remarks, Congresswoman Jacobs congratulated Firestorm, saying"I am so glad that Firestorm is opening its new headquarters in San Diego, creating jobs, spurring new investment opportunities, and driving forward innovation to help our troops and allies identify and neutralize threats."
  • Representative Jacobs and guests were given special access to explore Firestorm's technology and witness their commitment to tackling evolving defense needs.
  • "Firestorm is dedicated to delivering state-of-the-art defense capabilities that meet the challenges of today's complex security landscape head on," said Magy.

Convergent Therapeutics Announces FDA Clearance of IND Application for CONV01-α, a Best-in-Class Radioantibody Targeting Prostate-Specific Membrane Antigen

Retrieved on: 
Tuesday, April 2, 2024
Radiation, Convergent, Prostate cancer, Patient, IND, Alpha, Therapy, Cancer, Safety, CSO, PSA, FDA, Food, Pharmaceutical industry

CAMBRIDGE, Mass., April 2, 2024 /PRNewswire/ -- Convergent Therapeutics Inc., a clinical stage biotechnology company focused on developing next generation radiopharmaceutical therapies for the treatment of prostate cancer and other cancers, today announced that the U.S. Food and Drug Administration ("FDA") has cleared the investigational new drug ("IND") application for CONV01-α, its lead candidate for the treatment of patients with advanced prostate cancer.

Key Points: 
  • "Receiving clearance of our IND is a significant milestone for Convergent Therapeutics," said Convergent's Co-founder and CEO, Philip Kantoff, MD.
  • "Importantly, patients also showed minimal side effects in Phase 1/2 trials.
  • CONV01-α's ideal biodistribution delivers potent alpha particles while avoiding immediate and significant salivary gland toxicity as well as the potential delayed renal toxicity," said Neil Bander, MD, Convergent's Co-founder and CSO.
  • "CONV01-α's design increases delivery of tumor-killing radiation to malignant cells while greatly reducing both off-tumor effects and the amount of radiation delivered per dose, thereby improving both treatment efficacy and safety."

GC Cell to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024

Retrieved on: 
Tuesday, April 2, 2024
Patient, Research, Abstract, CD5, AACR, T-cell lymphoma, Division, CSO, Hematology, Vaccine

"We are looking forward to sharing data that GL205 (GCC2005) effectively targets CD5 in malignant T-cell lymphomas, suggesting it as a new treatment option for patients with limited choices from current approved therapies.

Key Points: 
  • "We are looking forward to sharing data that GL205 (GCC2005) effectively targets CD5 in malignant T-cell lymphomas, suggesting it as a new treatment option for patients with limited choices from current approved therapies.
  • Presenting at AACR offers a significant opportunity to globally disseminate our research findings, creating anticipation for the forthcoming clinical trials of GL205 (GCC2005) slated for IND submission this year."
  • said Sungyong Won, CSO of GC Cell.
  • Details for the AACR 2024 abstracts are as follows:
    Title: Superior anti-tumor activity of GL205, an allogeneic anti-CD5 CAR-NK for treating T-cell malignancies
    Lead Author: Jong Gwon Choi, Division of Oncology and Hematology, Konyang University Hospital, Daejeon, Korea

Hansa Biopharma Expects Strong First Quarter 2024 Sales Performance

Retrieved on: 
Tuesday, April 2, 2024
Sarepta Therapeutics, Interest, Growth, CFO, CCO, CSO, Person

LUND, Sweden, April 2, 2024 /PRNewswire/ -- Hansa Biopharma AB (STO: HNSA) expects to report revenue of approximately SEK 54m for Q1 ending March 31, 2024 (preliminary and unaudited), consisting of SEK 48m in product sales and SEK 6m in revenue recognition primarily related to its agreement with Sarepta Therapeutics, Inc. Revenue growth during the first quarter 2024 was driven by product sales in the Company's largest markets including France, UK, and Germany, as well as initial sales in Belgium.

Key Points: 
  • LUND, Sweden, April 2, 2024 /PRNewswire/ -- Hansa Biopharma AB (STO: HNSA) expects to report revenue of approximately SEK 54m for Q1 ending March 31, 2024 (preliminary and unaudited), consisting of SEK 48m in product sales and SEK 6m in revenue recognition primarily related to its agreement with Sarepta Therapeutics, Inc. Revenue growth during the first quarter 2024 was driven by product sales in the Company's largest markets including France, UK, and Germany, as well as initial sales in Belgium.
  • Søren Tulstrup, President and CEO, Hansa Biopharma, said: "Q1 represents a strong start to the year with solid product sales for the second quarter in a row and the best IDEFIRIX® product sales recorded in a quarter.
  • The Company will publish Q1 2024 results on April 18, 2024.
  • The information was submitted for publication, through the contact persons set out below, at 07:00: CET on April 2, 2024.

Hansa Biopharma Expects Strong First Quarter 2024 Sales Performance

Retrieved on: 
Tuesday, April 2, 2024
Sarepta Therapeutics, Interest, Growth, CFO, CCO, CSO, Person

LUND, Sweden, April 2, 2024 /PRNewswire/ -- Hansa Biopharma AB (STO: HNSA) expects to report revenue of approximately SEK 54m for Q1 ending March 31, 2024 (preliminary and unaudited), consisting of SEK 48m in product sales and SEK 6m in revenue recognition primarily related to its agreement with Sarepta Therapeutics, Inc. Revenue growth during the first quarter 2024 was driven by product sales in the Company's largest markets including France, UK, and Germany, as well as initial sales in Belgium.

Key Points: 
  • LUND, Sweden, April 2, 2024 /PRNewswire/ -- Hansa Biopharma AB (STO: HNSA) expects to report revenue of approximately SEK 54m for Q1 ending March 31, 2024 (preliminary and unaudited), consisting of SEK 48m in product sales and SEK 6m in revenue recognition primarily related to its agreement with Sarepta Therapeutics, Inc. Revenue growth during the first quarter 2024 was driven by product sales in the Company's largest markets including France, UK, and Germany, as well as initial sales in Belgium.
  • Søren Tulstrup, President and CEO, Hansa Biopharma, said: "Q1 represents a strong start to the year with solid product sales for the second quarter in a row and the best IDEFIRIX® product sales recorded in a quarter.
  • The Company will publish Q1 2024 results on April 18, 2024.
  • The information was submitted for publication, through the contact persons set out below, at 07:00: CET on April 2, 2024.

Olympus Corporation of the Americas' Julien Sauvagnargues Steps into CEO Role

Retrieved on: 
Wednesday, March 27, 2024
Grifols, Nachos, Olympus Corporation, AdvaMed, OCA, CSO, Medtech, Corporation, Management

CENTER VALLEY, Pa., March 27, 2024 /PRNewswire/ -- Olympus, a leading global MedTech company providing innovative solutions for medical and surgical procedures, announced today the appointment of Julien Sauvagnargues to the role of President and Chief Executive Officer (CEO), Olympus Corporation of the Americas (OCA), reporting to Olympus Chief Strategy Officer (CSO), Gabriela Kaynor, effective April 1, 2024.

Key Points: 
  • This new step in Mr. Sauvagnargues' career at Olympus, which began in 2006, builds upon his tenure as OCA President since 2020.
  • Mr. Glavin came to Olympus in 2016 in a consultant role and became the OCA Chief Compliance Officer that same year.
  • These leadership changes are in part due to the departure from Olympus of Nacho Abia, former OCA CEO and global CSO.
  • "We cannot be grateful enough for Nacho's 23-year tenure with this company," said Stefan Kaufmann, CEO, Olympus Corporation.

Just Style Applauds Centric Software for AI Innovations and More with 4 Awards

Retrieved on: 
Tuesday, March 26, 2024
Style, Innovation, Development, EVP, Intelligence, Data analysis, GlobalData, PLM, Centric Software, Acquisition, AI, Product lifecycle, Foodservice, Research and development, Investment, Cosmetics, CSO

CAMPBELL, Calif., March 26, 2024 /PRNewswire-PRWeb/ -- Centric Software®, the Product Lifecycle Management (PLM) market leader is pleased to announce that it has been awarded four accolades in the Just Style Excellence Awards 2024. Centric Software provides the most innovative enterprise solutions to plan, design, develop, source, buy, make, price, allocate, sell and replenish products such as fashion, outdoor, luxury, multi-category retail, grocery, food & beverage, cosmetics & personal care and consumer electronics to achieve strategic and operational digital transformation goals.

Key Points: 
  • Centric Software received four awards from Just Style in 2023, and has repeated the feat this year.
  • Centric is a Category Award Winner for Innovation, Product Launches, Research & Development and M&A in the Just Style Excellence Awards 2024.
  • "We are delighted that Just Style appreciates how Centric has embraced AI innovations," says Ron Watson, EVP, Products and CSO at Centric Software.
  • "We would like to thank Just Style for recognizing Centric's commitment to excellence with these four awards," says Chris Groves, CEO of Centric Software.

William Thomas Digital Embarks on Next Phase of Growth with Strategic Leadership Additions

Retrieved on: 
Friday, March 22, 2024
Microsoft, CRM, Val, Growth, IKEA, Volkswagen, GSK, WTD, Marketing, No Fixed Address, CSO, President's Choice Financial, Management

TORONTO, March 22, 2024 /CNW/ - William Thomas Digital Inc. (WTD), a leading agency in personalized customer experiences, is happy to announce a series of strategic leadership changes designed to fuel its ambitious growth plans and reinforce its industry-leading position in CX marketing.

Key Points: 
  • TORONTO, March 22, 2024 /CNW/ - William Thomas Digital Inc. (WTD), a leading agency in personalized customer experiences, is happy to announce a series of strategic leadership changes designed to fuel its ambitious growth plans and reinforce its industry-leading position in CX marketing.
  • His prior role as CSO at Wunderman Thompson Canada underscores his experience and ability to drive strategic innovation at the highest levels.
  • Kevin's vision and leadership will be instrumental in further advancing WTD's mission to lead the industry in delivering data-driven, personalized customer experiences.
  • These strategic leadership changes underscore WTD's dedication to excellence, innovation, and its vision for the future, affirming the agency's position at the forefront of the personalized customer experience industry.

Mission success: Ritonavir crystallization experiments conducted in space worked flawlessly

Retrieved on: 
Friday, March 22, 2024
Form, Mission, Spacecraft, Ritonavir, CSO, Varda Space Industries, Pharmaceutical industry

WEST LAFAYETTE, Ind., March 22, 2024 /PRNewswire-PRWeb/ -- Improved Pharma and Varda Space Industries have published the first mission results in ChemRxiv in an article entitled Return of the Ritonavir: A Study on the Stability of Pharmaceuticals Processed in Orbit and Returned to Earth. The team reports that the most stable form of ritonavir (Form II) was successfully converted to the metastable Form III in microgravity. In addition, control samples of Form I, Form II, Form III, and amorphous ritonavir that were also part of the payload were successfully recovered, with no signs of form conversion.

Key Points: 
  • The team reports that the most stable form of ritonavir (Form II) was successfully converted to the metastable Form III in microgravity.
  • In addition, control samples of Form I, Form II, Form III, and amorphous ritonavir that were also part of the payload were successfully recovered, with no signs of form conversion.
  • These results from Mission 1 show that the spacecraft and crystallization hardware performed flawlessly.
  • Analytical testing at Improved Pharma confirmed that the space crystallization experiments were a success, and that the physical stability of all samples was preserved.

Fluent BioSciences awarded NIH SBIR grant to commercialize low-cost million-cell transcriptome profiling kits powered by Ultima Genomics sequencing, prototype kits now shipping

Retrieved on: 
Thursday, March 21, 2024
Single-cell analysis, Stem cell, Growth, Cell, WUSTL, Associate, Partnership, Microfluidics, SBIR, Fluency, NIGMS, Genomics, CRISPR, CSO, Fine chemical

This funding will support the commercialization of million-cell analysis kits enabled by low-cost, high-capacity sequencing by Ultima Genomics.

Key Points: 
  • This funding will support the commercialization of million-cell analysis kits enabled by low-cost, high-capacity sequencing by Ultima Genomics.
  • Ultima Genomics sequencing of the prototype million-cell PIPseq data revealed clonal lineage trees with restriction of specific cell reprogramming fates.
  • "The collaboration between Fluent BioSciences and Ultima represents a remarkable synergy in pushing the boundaries of single-cell analysis," said Brian McKernan, CEO of Fluent BioSciences.
  • To learn more about Fluent BioSciences' million-cell PIPseq prototype kits and how they can empower high-throughput single-cell profiling, please contact [email protected] .